ARTICLE | Product Development
The Phase III trials and pharma sales most likely to be disrupted by COVID-19
A look at pharma revenues and Phase III trials in China reveals who could be hit hardest by COVID-19
February 15, 2020 4:17 AM UTC
Updated on Mar 20, 2020 at 8:48 PM UTC
The coronavirus outbreak comes at a time when many major multinational pharmas are betting big on the China market for future growth. In an analysis of MNC revenues and dependence on trial sites in China, BioCentury zooms in on who is likely to be hit the hardest.
On the revenue front, AstraZeneca plc (LSE:AZN; NYSE:AZN) has by far the largest sales in -- and exposure to -- China. With 21% of the pharma’s 2019 product sales coming from China, the region is now its second-biggest, and fastest growing, revenue driver (see Figure: “Biopharma Revenues from China”)...